Senti Biosciences, Inc. 8-K

What Happened

• Senti Biosciences, Inc. announced plans to implement a holding company reorganization expected to become effective by April 16, 2026. The plan calls for a tax‑free merger of the company into a new merger subsidiary, with newly formed Senti Holdings, Inc. and Senti Biosciences Holdings, Inc. layered above it so that Senti Biosciences Holdings will become the successor issuer.
• Under the reorganization each outstanding share of Senti Biosciences’ common stock (par value $0.0001) would automatically convert into an equivalent share of Senti Biosciences Holdings’ common stock with the same rights and preferences. The conversion is automatic, requires no shareholder vote under Delaware General Corporation Law Section 251(g), and is intended to be tax‑free for U.S. federal income tax purposes.
• After the reorganization, the company says the new holding company will have the same directors, officers, assets and operations as before. Trading on the Nasdaq Capital Market is expected to continue uninterrupted under the symbol “SNTI,” though the shares will have a new CUSIP.

Key Details

• Expected effective date: on or about April 16, 2026 (subject to change or cancellation).
• Legal basis: Delaware GCL Section 251(g) — formation of a holding company without a stockholder vote.
• Stock conversion: one-to-one automatic conversion of existing Senti Biosciences common stock into Senti Biosciences Holdings common stock.
• Tax treatment: conversion expected to be tax‑free for U.S. federal income tax purposes; trading to continue under ticker “SNTI” with a new CUSIP.

Why It Matters

• For investors, this is primarily a structural change: shareholders will own the same economic interest and face the same management, operations and board, but through a new holding company entity.
• Trading continuity means holders should not need to sell or re-register shares to remain invested, though the security will have a new CUSIP.
• Because the conversion is automatic and requires no vote, shareholders do not need to take action—however, the company notes the reorganization could be delayed or not implemented.